Oncolytics Biotech (ONCY) Share-based Compensation (2009 - 2025)
Oncolytics Biotech (ONCY) posted quarterly Share-based Compensation of $3.0 million for Q3 2025, up 817.29% year-over-year from $326208.8 in Q3 2024, and up 692.75% quarter-over-quarter from $377455.6 in Q2 2025.
Oncolytics Biotech (ONCY) Share-based Compensation (2009 - 2025) Analysis & Trends
Oncolytics Biotech (ONCY) has reported Share-based Compensation for 17 consecutive years, with $3.0 million the latest figure, recorded in Q3 2025.
- In Q3 2025, Share-based Compensation rose 817.29% year-over-year to $3.0 million; the TTM figure through Sep 2025 stood at $5.1 million (up 351.02% YoY), while the FY2025 annual figure was $3.1 million, changed N/A from the prior year.
- Share-based Compensation advanced to $3.0 million in Q3 2025 per ONCY's latest filing, from $377455.6 in the prior quarter.
- Across five years, Share-based Compensation topped out at $3.0 million in Q3 2025 and bottomed at -$2.1 million in Q4 2021.
- Historically, Share-based Compensation has averaged $452529.9 across 5 years, with a median of $405935.6 in 2022.
- Annual changes were most pronounced in 2021 — Share-based Compensation tumbled 263.67% — and 2025, when it surged 817.29%.
- Oncolytics Biotech's Share-based Compensation stood at -$2.1 million in 2021, then soared by 125.79% to $551790.5 in 2022, then slumped by 155.15% to -$304339.6 in 2023, then surged by 381.32% to $856155.6 in 2024, then soared by 249.5% to $3.0 million in 2025.
- Business Quant data shows ONCY's Share-based Compensation at $3.0 million in Q3 2025, $377455.6 in Q2 2025, and $841875.1 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Oncolytics Biotech | 96.23 Mn | 96.23 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 2.99 Mn |
| Sep 30, 2025 | 2.99 Mn |
| Jun 30, 2025 | 377,455.64 |
| Jun 30, 2025 | 377,455.64 |
| Mar 31, 2025 | 841,875.10 |
| Mar 31, 2025 | 841,875.10 |
| Dec 31, 2024 | 856,155.57 |
| Dec 31, 2024 | 856,155.57 |
| Sep 30, 2024 | 326,208.77 |
| Sep 30, 2024 | 326,208.77 |
| Jun 30, 2024 | 369,957.12 |
| Jun 30, 2024 | 369,957.12 |
| Mar 31, 2024 | 427,457.21 |
| Mar 31, 2024 | 427,457.21 |
| Sep 30, 2023 | -304,339.63 |
| Sep 30, 2023 | -304,339.63 |
| Jun 30, 2023 | 180,157.50 |
| Jun 30, 2023 | 180,157.50 |
| Mar 31, 2023 | 234,483.75 |
| Mar 31, 2023 | 234,483.75 |